SG10201405039VA - Method of treating cancer - Google Patents

Method of treating cancer

Info

Publication number
SG10201405039VA
SG10201405039VA SG10201405039VA SG10201405039VA SG10201405039VA SG 10201405039V A SG10201405039V A SG 10201405039VA SG 10201405039V A SG10201405039V A SG 10201405039VA SG 10201405039V A SG10201405039V A SG 10201405039VA SG 10201405039V A SG10201405039V A SG 10201405039VA
Authority
SG
Singapore
Prior art keywords
treating cancer
cancer
treating
Prior art date
Application number
SG10201405039VA
Other languages
English (en)
Inventor
Nan Bing
Linda Perry Briley
Laura R Budde
Charles J Cox
Colin F Spraggs
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201405039V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of SG10201405039VA publication Critical patent/SG10201405039VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
SG10201405039VA 2009-08-21 2010-08-20 Method of treating cancer SG10201405039VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23594709P 2009-08-21 2009-08-21
US30756910P 2010-02-24 2010-02-24

Publications (1)

Publication Number Publication Date
SG10201405039VA true SG10201405039VA (en) 2014-10-30

Family

ID=43607603

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201405039VA SG10201405039VA (en) 2009-08-21 2010-08-20 Method of treating cancer
SG2012010658A SG178439A1 (en) 2009-08-21 2010-08-20 Method of treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012010658A SG178439A1 (en) 2009-08-21 2010-08-20 Method of treating cancer

Country Status (26)

Country Link
US (3) US20120156200A1 (ja)
EP (1) EP2467140B1 (ja)
JP (1) JP5876827B2 (ja)
KR (1) KR101781658B1 (ja)
CN (1) CN102770140B (ja)
AU (2) AU2010284092A1 (ja)
BR (1) BR112012003653A2 (ja)
CA (2) CA2771699C (ja)
CY (1) CY1118486T1 (ja)
DK (1) DK2467140T3 (ja)
EA (1) EA027959B1 (ja)
ES (1) ES2589377T3 (ja)
HR (1) HRP20161110T1 (ja)
HU (1) HUE029098T2 (ja)
IL (1) IL218230B (ja)
LT (1) LT2467140T (ja)
ME (1) ME02492B (ja)
MX (1) MX367580B (ja)
PL (1) PL2467140T3 (ja)
PT (1) PT2467140T (ja)
RS (1) RS55074B1 (ja)
SG (2) SG10201405039VA (ja)
SI (1) SI2467140T1 (ja)
SM (1) SMT201600296B (ja)
WO (1) WO2011022633A2 (ja)
ZA (1) ZA201201110B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035540A1 (zh) 2009-09-28 2011-03-31 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物
KR20140117644A (ko) * 2012-01-31 2014-10-07 스미스클라인 비이참 (코르크) 리미티드 암을 치료하는 방법
GB201403820D0 (en) * 2014-03-04 2014-04-16 Isis Innovation Assay
CN104293958B (zh) * 2014-10-16 2016-09-21 卫生部北京医院 一种预测强直性脊柱炎易感性的试剂盒和方法
BR112019012203A2 (pt) * 2016-12-14 2019-11-12 Beijing Genomics Inst At Shenzhen marcadores genéticos humanos associados à resposta para tratamentos que têm como alvo a toxina b de clostridium difficile

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
JP2000508912A (ja) 1996-04-19 2000-07-18 スペクトラ バイオメディカル,インコーポレイテッド 多型形態と複数の表現型との相関付け
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
AR031248A1 (es) 2000-06-30 2003-09-17 Glaxo Group Ltd Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US7794960B2 (en) * 2004-06-04 2010-09-14 Glaxosmithkline Llc Predictive biomarkers in cancer therapy
JP2007117085A (ja) 2005-09-28 2007-05-17 Genodive Pharma Kk 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法
EP1988164A4 (en) 2006-02-23 2009-04-22 Univ Kanazawa Nat Univ Corp METHOD FOR TESTING THE SENSITIVITY OF SOLIC CANCER AGAINST A TYROSINE KINASE INHIBITOR AND CORRESPONDING TEST REQUIREMENTS
WO2008070448A2 (en) * 2006-11-22 2008-06-12 Board Of Regents, The University Of Texas System Cancer-specific promoters
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20110286997A1 (en) * 2007-03-13 2011-11-24 Hakon Hakonarson Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes

Also Published As

Publication number Publication date
IL218230B (en) 2019-02-28
US20150231137A1 (en) 2015-08-20
WO2011022633A2 (en) 2011-02-24
SMT201600296B (it) 2016-11-10
US20120156200A1 (en) 2012-06-21
EP2467140A2 (en) 2012-06-27
RS55074B1 (sr) 2016-12-30
JP2013502433A (ja) 2013-01-24
AU2014203270A1 (en) 2014-07-10
EP2467140B1 (en) 2016-06-01
EP2467140A4 (en) 2013-11-06
AU2014203270B2 (en) 2016-06-16
CA2771699C (en) 2022-03-29
CA3080511A1 (en) 2011-02-24
ZA201201110B (en) 2012-10-31
EA201270298A1 (ru) 2012-12-28
JP5876827B2 (ja) 2016-03-02
KR101781658B1 (ko) 2017-10-23
PL2467140T3 (pl) 2017-04-28
AU2010284092A1 (en) 2012-03-08
CA3080511C (en) 2022-05-24
ES2589377T3 (es) 2016-11-14
HRP20161110T1 (hr) 2016-11-04
US20170065590A1 (en) 2017-03-09
PT2467140T (pt) 2016-08-30
DK2467140T3 (en) 2016-09-05
SI2467140T1 (sl) 2016-10-28
EA027959B1 (ru) 2017-09-29
ME02492B (me) 2017-02-20
WO2011022633A3 (en) 2012-12-27
HUE029098T2 (en) 2017-02-28
CN102770140B (zh) 2017-06-23
US9539257B2 (en) 2017-01-10
MX367580B (es) 2019-08-27
BR112012003653A2 (pt) 2016-03-22
US10004742B2 (en) 2018-06-26
LT2467140T (lt) 2016-09-12
MX2012002161A (es) 2012-07-17
IL218230A0 (en) 2012-04-30
CA2771699A1 (en) 2011-02-24
CN102770140A (zh) 2012-11-07
CY1118486T1 (el) 2017-07-12
KR20120059564A (ko) 2012-06-08
SG178439A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
IL218575A0 (en) Treatment of cancer
EP2643001A4 (en) METHOD OF TREATING CANCER
IL223189A0 (en) Methods of treatment of pancreatic cancer
PT2434891T (pt) Métodos para tratamento de cancro e afeções não neoplásicas
HK1217763A1 (zh) 用於治療疾病的方法
HK1189272A1 (zh) 治療癌症的方法
EP2480579A4 (en) METHODS OF TREATING INFLAMMATION
EP2640390A4 (en) METHODS OF TREATING CANCER
IL215037A0 (en) Treatment of pancreatic cancer
IL218230A0 (en) Method of treating cancer
ZA201108493B (en) Method of treating hair
EP2560648A4 (en) METHOD OF TREATING PANCREATIC CANCER
EP2509599A4 (en) METHOD FOR THE TREATMENT OF PANCREATIC CANCER
EP2593100A4 (en) METHOD OF TREATING REFRACTORY CANCER
EP2560639A4 (en) METHOD FOR THE TREATMENT OF PROSTATE CANCER
IL213919A0 (en) Methods to treat cancer
GB0916686D0 (en) Treatment of cancer
EP2560638A4 (en) METHOD OF TREATING GASTRIC CANCER
EP2440238A4 (en) Methods of Treatment
GB0921823D0 (en) Method of treatment
GB0909807D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment
GB0921757D0 (en) Treatment of cancer
IL216629A0 (en) Methods of treating inflammation